Editas Medicine (EDIT) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Editas Medicine (EDIT) has outperformed Kyverna Therapeutics (KYTX) over the past year, losing 32.2% versus a loss of 39.9%. Kyverna Therapeutics is the larger company by market cap ($269.3 million vs $253.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | KYTX |
|---|---|---|
| Share price | $1.64 | $4.26 |
| Market cap | $253.12M | $269.33M |
| 1-day change | -4.09% | -2.52% |
| YTD return | -20.00% | -54.68% |
| 1-year return | -32.23% | -39.92% |
| 5-year return | -94.93% | — |
| EPS (TTM) | $-0.54 | $-2.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.52M | — |
| Revenue growth (YoY) | +25.39% | — |
| Net income (latest FY) | $-160.06M | $-161.31M |
| Operating margin | -394.89% | — |
| Net margin | -395.01% | — |
| 52-week high | $3.94 | $13.67 |
| 52-week low | $1.63 | $4.18 |
| Distance from 52-week high | -58.38% | -68.84% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +271.95% | +613.62% |
| Average volume | 2.63M | 867.28K |
| Shares outstanding | 154.34M | 63.22M |
| Employees | 87 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees
EDIT vs KYTX FAQ
Which is bigger, Editas Medicine or Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $269.33M compared with $253.12M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or KYTX?
EDIT returned -32.23% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.